Articles related to Hepatology

Liver injuries tied to botanical supplements are on the rise, with cases nearly tripling in a decade. Healthcare providers should be aware of this growing concern and its implications for patient care.

In patients with both cirrhosis and atrial fibrillation, apixaban initiation was associated with lower rates of major bleeding compared to rivaroxaban or warfarin, without compromising thromboembolic protection.

Despite its theoretical benefits, IV albumin has not shown consistent superiority over crystalloid solutions in sepsis management, prompting a reevaluation of fluid resuscitation strategies in critical care settings.

Incidence rates provide a truer measure of medication-induced liver injury, revealing misclassifications in traditional methods. This study highlights the need for closer monitoring of certain medications using real-world healthcare data.

Integrating telehealth into opioid treatment programs drastically improves hepatitis C cure rates, particularly among underserved populations, by facilitating seamless access to DAAs and continuous follow-up care.

A phase 2 trial found that tirzepatide, administered once weekly, significantly improved the resolution of MASH and fibrosis stages in patients with moderate to severe liver fibrosis. These results highlight tirzepatide’s potential as a treatment option, emphasizing the need for further research to validate these findings in larger, long-term studies.